IP Library › Patent Application 11981732
Patent Application
App. No. 11/981,732

Method for diagnosing efficacy of xenotypic antibody therapy

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/981,732
Abstract

The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.

Claims (22)

1 . A method for treating cancer comprising

contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and

allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.

2 . The method of claim 1 wherein the binding reagent comprises a monoclonal antibody.

3 . The method of claim 2 wherein the target multi-epitopic tumor associated antigen is CA 125.

4 . The method of claim 2 wherein the target multi-epitopic tumor associated antigen is CA 19.9.

5 . The method of claim 2 wherein the target multi-epitopic tumor associated antigen is CA 15.3.

6 . The method of claim 1 wherein the tumor-associated antigen is an ovarian tumor antigen.

7 . The method of claim 1 wherein the host immune response is a cellular immune response.

8 . The method of claim 1 wherein the host immune response is a humoral immune response.

9 . The method of claim 1 wherein the host immune response is both a humoral immune response and a cellular response.

10 . A method for eliciting an immune response comprising

contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and

allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.

11 . A method for increasing the immunogenicity of an antigen comprising

contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and

allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.

12 . A method for re-conforming a multi-epitopic tumor associated antigen expressed in a host serum and for recognizing and initiating an immune response, comprising contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and

allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.

13 . A delivery system for a multi-epitopic tumor associated antigen expressed in a host serum, and for recognizing and initiating an immune response, comprising a composition comprising a binding reagent that specifically binds to a single epitope on a multi-epitopic tumor-associated antigen.

14 . The method of claim 1 wherein the formation of the reagent-antigen pair elicits a host immune response that overcomes tolerance of the antigen.

15 . The method of claim 1 wherein the contacting step is ex vivo or in vivo.